Analyst Price Targets — ANAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 31, 2026 9:37 am | Andy Chen | Wolfe Research | $78.00 | $56.28 | StreetInsider | Wolfe Research Reiterates Outperform Rating on AnaptysBio (ANAB) |
| August 25, 2026 11:37 am | — | Scotiabank | $70.00 | $58.44 | StreetInsider | AnaptysBio (ANAB) PT Lowered to $70 at TD Cowen |
| May 15, 2026 2:51 pm | — | Leerink Partners | $90.00 | $62.65 | TheFly | AnaptysBio price target raised to $90 from $85 at Leerink |
| May 13, 2026 11:33 am | — | UBS | $76.00 | $65.58 | TheFly | AnaptysBio price target raised to $76 from $60 at UBS |
| May 13, 2026 8:56 am | — | Barclays | $75.00 | $65.58 | TheFly | AnaptysBio price target raised to $75 from $63 at Barclays |
| April 28, 2026 10:21 am | — | Leerink Partners | $85.00 | $66.59 | TheFly | AnaptysBio price target raised to $85 from $66 at Leerink |
| April 21, 2026 12:28 pm | — | UBS | $60.00 | $54.23 | TheFly | AnaptysBio price target lowered to $60 from $90 at UBS |
| March 6, 2026 2:07 pm | John Lee | Truist Financial | $50.00 | $56.29 | StreetInsider | AnaptysBio (ANAB) PT Raised to $50 at Truist Securities on improved outlook for Jemperli |
| March 5, 2026 11:54 am | Alex Thompson | Stifel Nicolaus | $85.00 | $57.36 | StreetInsider | AnaptysBio (ANAB) PT Raised to $85 at Stifel After Q4 Update |
| March 4, 2026 11:41 am | Emily Bodnar | H.C. Wainwright | $66.00 | $58.04 | StreetInsider | AnaptysBio (ANAB) PT Raised to $66 at H.C. Wainwright |
Latest News for ANAB
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET.
Canada Pension Plan Investment Board purchased a new stake in AnaptysBio, Inc. (NASDAQ: ANAB) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 16,500 shares of the biotechnology company's stock, valued at approximately $1,114,000. Canada Pension Plan Investment Board owned
GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.
AnaptysBio is now a focused royalty management company, with its value tied primarily to Jemperli royalties from GSK. Post-spin, ANAB operates virtually with a 95% targeted EBIT margin and over $140M net cash, eliminating prior R&D burn. Jemperli royalties escalate with sales, and once the Sagard obligation is paid (expected by mid-2027), ANAB will retain high-margin, growing royalty streams.
AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) rose 5.3% during mid-day trading on Friday. The company traded as high as $56.54 and last traded at $57.00. 47,244 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 753,749 shares. The stock had previously closed at $54.15. Analysts Set
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANAB.
U.S. House Trading
No House trades found for ANAB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.